Mild to moderate liver dysfunction does not require dose reduction of oral or intravenous vinorelbine: Results of a pharmacokinetic study

European Journal of Cancer

Volumn 46, Issue 2, 2010, Pages 266-269

  Kitzen, Jos J ^a   Puozzo, Christian ^b   de Jonge, Maja J ^a   Brandely, Maud ^b   Verweij, Jaap ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b INSTITUT DE RECHERCHE PIERRE FABRE   (France)

Author keywords

Intravenous; Oral; Pharmacokinetic; Toxicity; Vinorelbine

Indexed keywords

NAVELBINE;

AREA UNDER THE CURVE; ARTICLE; BLOOD TOXICITY; CLINICAL ARTICLE; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFECT; GASTROINTESTINAL TOXICITY; HUMAN; LIVER DYSFUNCTION; MAXIMUM PLASMA CONCENTRATION; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; RANDOMIZATION; SOLID TUMOR; TIME TO MAXIMUM PLASMA CONCENTRATION;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BIOLOGICAL AVAILABILITY; HUMANS; INFUSIONS, INTRAVENOUS; LIVER DISEASES; MIDDLE AGED; NEOPLASMS; VINBLASTINE; YOUNG ADULT;

EID: 72449169643     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2009.10.031     Document Type: Article

References (10)

1. Lucas S., Donehouwer R., and Rowinsky E. Absolute bioavailability (ABA) and pharmacokinetics (PK) of weekly Navelbine (NVB) liquid-filled soft gelatine capsules at full therapeutic doses in patients with solid tumors. Ann Oncol 3 Suppl. 1 (1992) 125
2. Marty M., Fumoleau P., Adenis A., et al. Oral vinorelbine pharmacokinetics and absolute bioavailability study in patients with solid tumors. Ann Oncol 12 11 (2001) 1643-1649
3. Queisser W., Doss A., Wander H.E., et al. Phase II study of vinorelbine by oral route (in a hard gelatine capsule) for metastatic breast cancer patients. A trial of the phase I/II study group of the Association for Medical Oncology of the German Cancer Society. Onkologie 14 1 (1991) 35-39
4. Baweja M., Suman V.J., Fitch T.R., et al. Phase II trial of oral vinorelbine for the treatment of metastatic breast cancer in patients ≥65 years of age: an NCCTG study. Ann Oncolog 17 (2006) 623-629
5. Gridelli C., Manegold C., Mali P., et al. Oral vinorelbine given as monotherapy to advanced, elderly NSCLC patients: a multicentre phase II trial. Eur J Cancer 40 (2004) 2424-2431
6. Kanard A., Jatoi A., Castillo R., et al. Oral vinorelbine for the treatment of metastatic non-small cell lung cancer in elderly patients: a phase II trial of efficacy and toxicity. Lung Cancer 43 3 (2004) 345-353
7. Freyer G., Delozier T., Lichinister M., et al. Phase II study of oral vinorelbine in first-line advanced breast cancer chemotherapy. J Clin Oncol 21 (2003) 35-40
8. Robieux I., Sorio R., Borsatti E., et al. Pharmacokinetics of vinorelbine in patients with liver metastases. Clin Pharmacol Ther 59 1 (1996) 32-40
9. Focan C., Kreutz F., Leroy I., et al. Pharmacokinetics and mass-balance elimination of 3H-vinorelbine following IV and oral administration to patients. Proc AACR (2001) [Abst. 2064]
10. Beulz-Riché D., Grudé P., Puozzo C., et al. Characterisation of human cytochrome P450 isoenzymes involved in the metabolism of vinorelbine. Fundam Clin Pharmacol 19 (2005) 545-553